USD 4.77
↓ -0.18 (-3.64%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| INO | -3.6 | -13.6 | -14.5 | -38.8 | -63.5 | 4.6 | -94.6 | -83.1 | -96.0 | -99.3 |
| S&P 500 | -0.6 | -0.5 | 2.3 | 7.3 | 12.1 | 32.1 | 27.0 | 90.7 | 191.4 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | INO |
| name | Inovio Pharmaceuticals, Inc. |
| price | 4.77 |
| changes percentage | -3.64 |
| change | -0.18 |
| day low | 4.76 |
| day high | 5.05 |
| year high | 14.75 |
| year low | 4.20 |
| market cap | 123849711 |
| price avg 50 | 5.83 |
| price avg 200 | 8.68 |
| exchange | NASDAQ |
| volume | 646098 |
| avg volume | 301207 |
| open | 4.95 |
| previous close | 4.95 |
| eps | -5.07 |
| pe | -0.94 |
| earnings announcement | 2024-11-14T21:00:00.000+0000 |
| shares outstanding | 25964300 |
| timestamp | 2024-11-14 21:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001055726 | |||
| revenue | 832010 | 10262268 | -91.89 |
| gross profit | -2671528 | 4766242 | -156.05 |
| gross profit ratio | -3.21 | 0.46 | -791.35 |
| research and development expenses | 88476563 | 187650503 | -52.85 |
| operating expenses | 132555129 | 277835788 | -52.29 |
| interest income | 8133290 | 4782030 | 70.08 |
| interest expense | 1222789 | 1253952 | -2.49 |
| ebitda | -130391024 | -270902876 | 51.87 |
| ebitdaratio | -156.72 | -26.17 | -498.87 |
| operating income | -135226657 | -267573520 | 49.46 |
| operating income ratio | -162.53 | -26.07 | -523.35 |
| net income | -135117352 | -287664237 | 53.03 |
| net income ratio | -162.4 | -28.03 | -479.35 |
| eps | -6.09 | -14.47 | 57.91 |
Revenue Growth: revenue increased to 1 million in 2023 from 10 million in 2022 representing a change of -91.89%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 88 million in 2023 from 188 million in 2022 representing a change of -52.85%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 133 million in 2023 from 278 million in 2022 representing a change of -52.29%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -6.09 in 2023 from -6.09 in 2022 representing a change of 57.91%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to -3 million in 2023 from 5 million in 2022 representing a change of -156.05%. This indicates a sales profitability decline, which is a negative sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -130 million in 2023 from -271 million in 2022 representing a change of 51.87%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -135 million in 2023 from -268 million in 2022 representing a change of 49.46%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -135 million in 2023 from -288 million in 2022 representing a change of 53.03%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001055726 | |||
| revenue | 0 | 100762 | -100.00 |
| gross profit | 0 | -727863 | 100.00 |
| gross profit ratio | 0 | -7.22 | 100.00 |
| research and development expenses | 18733584000 | 23090989 | 81,029.41 |
| operating expenses | 27347479000 | 32469050 | 84,126.30 |
| interest income | 1106758000 | 1307358 | 84,556.08 |
| interest expense | 0 | 0 | NaN |
| ebitda | -27347479000 | -31408470 | -86,970.40 |
| ebitdaratio | 0 | -311.71 | 100.00 |
| operating income | -27347479000 | -33196913 | -82,279.58 |
| operating income ratio | 0 | -329.46 | 100.00 |
| net income | -25165478000 | -32237098 | -77,963.72 |
| net income ratio | 0 | -319.93 | 100.00 |
| eps | -894.28 | -1.19 | -75,049.58 |
Revenue Growth: revenue decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -100.0%. This indicates a sales shrinking, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 18,734 million in 2024Q3 from 23 million in 2024Q2 representing a change of 81029.41%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -27,347 million in 2024Q3 from -31 million in 2024Q2 representing a change of -86970.4%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -27,347 million in 2024Q3 from -33 million in 2024Q2 representing a change of -82279.58%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -25,165 million in 2024Q3 from -32 million in 2024Q2 representing a change of -77963.72%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -894.28 in 2024Q3 from -894.28 in 2024Q2 representing a change of -75049.58%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from -1 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 27,347 million in 2024Q3 from 32 million in 2024Q2 representing a change of 84126.3%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001055726 | |||
| total assets | 172944423 | 348533302 | -50.38 |
| total liabilities | 55595294 | 126170546 | -55.94 |
| total equity | 117349129 | 222362756 | -47.23 |
| cash and cash equivalents | 14310862 | 46329359 | -69.11 |
| short term investments | 130982913 | 206669397 | -36.62 |
| long term investments | 2780287 | 2007142 | 38.52 |
| total current assets | 153113100 | 315242680 | -51.43 |
| total non current assets | 19831322 | 33290622 | -40.43 |
| total current liabilities | 42570228 | 96868074 | -56.05 |
| total non current liabilities | 13025066 | 29302472 | -55.55 |
| common stock | 22792 | 253090 | -90.99 |
| retained earnings | -1622965136 | -1487847784 | -9.08 |
| total debt | 30209242 | 32074399 | -5.82 |
Total Assets: Total Assets decreased to 173 million in 2023 from 349 million in 2022 representing a change of -50.38%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 117 million in 2023 from 222 million in 2022 representing a change of -47.23%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 14 million in 2023 from 46 million in 2022 representing a change of -69.11%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 131 million in 2023 from 207 million in 2022 representing a change of -36.62%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 153 million in 2023 from 315 million in 2022 representing a change of -51.43%. This indicates a worsen liquidity position.
Common Stock: Common Stock decreased to 0 in 2023 from 0 in 2022 representing a change of -90.99%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -1,623 million in 2023 from -1,488 million in 2022 representing a change of -9.08%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 56 million in 2023 from 126 million in 2022 representing a change of -55.94%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 43 million in 2023 from 97 million in 2022 representing a change of -56.05%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 30 million in 2023 from 32 million in 2022 representing a change of -5.82%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001055726 | |||
| total assets | 107059674000 | 133797203 | 79,916.38 |
| total liabilities | 33519364000 | 37057996 | 90,351.10 |
| total equity | 73540310000 | 96739207 | 75,919.14 |
| cash and cash equivalents | 21687480000 | 34392404 | 62,958.92 |
| short term investments | 63117288000 | 76029116 | 82,917.26 |
| long term investments | 0 | 2319975 | -100.00 |
| total current assets | 91284623000 | 117561045 | 77,548.70 |
| total non current assets | 15775051000 | 16236158 | 97,060.00 |
| total current liabilities | 23499137000 | 26399768 | 88,912.66 |
| total non current liabilities | 10020227000 | 10658228 | 93,914.00 |
| common stock | 26051000 | 25962 | 100,242.81 |
| retained earnings | -1710837583000 | -1685672105 | -101,392.90 |
| total debt | 12445339000 | 12980212 | 95,779.32 |
Total Assets: Total Assets increased to 107,060 million in 2024Q3 from 134 million in 2024Q2 representing a change of 79916.38%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 73,540 million in 2024Q3 from 97 million in 2024Q2 representing a change of 75919.14%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 21,687 million in 2024Q3 from 34 million in 2024Q2 representing a change of 62958.92%. This indicates an increase in available liquid assets.
Short Term Investments: Short Term Investments increased to 63,117 million in 2024Q3 from 76 million in 2024Q2 representing a change of 82917.26%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 91,285 million in 2024Q3 from 118 million in 2024Q2 representing a change of 77548.7%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 26 in 2024Q3 from 0 in 2024Q2 representing a change of 100242.81%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 33,519 million in 2024Q3 from 37 million in 2024Q2 representing a change of 90351.1%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 23,499 million in 2024Q3 from 26 million in 2024Q2 representing a change of 88912.66%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,710,838 million in 2024Q3 from -1,686 million in 2024Q2 representing a change of -101392.9%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 12,445 million in 2024Q3 from 13 million in 2024Q2 representing a change of 95779.32%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001055726 | |||
| net change in cash | -32018497 | -24814419 | -29.03 |
| operating cash flow | -124365551 | -216215421 | 42.48 |
| free cash flow | -124686449 | -217184574 | 42.59 |
| capital expenditure | -320898 | -969153 | 66.89 |
| depreciation and amortization | 3503538 | 5496026 | -36.25 |
| deferred income tax | -32046 | 4029961 | -100.80 |
| stock based compensation | 11072486 | 22555419 | -50.91 |
| accounts payables | -45989061 | 32606581 | -241.04 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 6219263 | -1999998 | 410.96 |
| investments in property plant and equipment | -320898 | -969153 | 66.89 |
| net cash used for investing activites | 87355875 | 109585856 | -20.29 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 5461745 | 82955311 | -93.42 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 4995099 | 81840702 | -93.90 |
| cash at end of period | 14310862 | 46329359 | -69.11 |
| accounts receivables | 9332988 | -3706172 | 351.82 |
| cash at beginning of period | 46329359 | 71143778 | -34.88 |
Net Change in Cash: Net Change in Cash decreased to -32 million in 2023 from -25 million in 2022 representing a change of -29.03%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from -1 million in 2022 representing a change of 66.89%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 46 million in 2023 from 33 million in 2022 representing a change of -241.04%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 9 in 2023 from -4 million in 2022 representing a change of 351.82%. This suggests that the company is less capable of collecting payments from its customers.
Operating Cash Flow: Operating Cash Flow increased to -124 million in 2023 from -216 million in 2022 representing a change of 42.48%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -125 million in 2023 from -217 million in 2022 representing a change of 42.59%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 11 million in 2023 from 23 million in 2022 representing a change of -50.91%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001055726 | |||
| operating cash flow | -84355674694 | -28209350 | -298,934.45 |
| free cash flow | -84355186862 | -28661604 | -294,214.26 |
| capital expenditure | 487832 | -452254 | 207.87 |
| depreciation and amortization | 2352624645 | 828625 | 283,819.10 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 5275304514 | 1514053 | 348,322.71 |
| accounts receivables | 541857437 | 777417 | 69,599.72 |
| accounts payables | -4338443955 | 798193 | -543,633.20 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 487832 | -452254 | 207.87 |
| net cash used for investing activites | 69371366051 | 9966314 | 695,958.40 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 22929582199 | 17059668 | 134,308.14 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 22308474504 | 33033611 | 67,432.65 |
| net change in cash | 21653087596 | 14790575 | 146,297.88 |
| cash at end of period | 21687480000 | 34392404 | 62,958.92 |
| cash at beginning of period | 34392404 | 19601829 | 75.46 |
Net Change in Cash: Net Change in Cash increased to 21,653 million in 2024Q3 from 15 million in 2024Q2 representing a change of 146297.88%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -84,356 million in 2024Q3 from -28 million in 2024Q2 representing a change of -298934.45%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -84,355 million in 2024Q3 from -29 million in 2024Q2 representing a change of -294214.26%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 207.87%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 5,275 million in 2024Q3 from 2 million in 2024Q2 representing a change of 348322.71%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 4,338 million in 2024Q3 from 1 million in 2024Q2 representing a change of -543633.2%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 542 in 2024Q3 from 1 million in 2024Q2 representing a change of 69599.72%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.04 | 0.52 | -92.73 |
| net income per share | -6.09 | -14.47 | 57.88 |
| operating cash flow per share | -5.61 | -10.87 | 48.42 |
| free cash flow per share | -5.62 | -10.92 | 48.52 |
| cash per share | 6.55 | 12.72 | -48.50 |
| book value per share | 5.29 | 11.18 | -52.67 |
| tangible book value per share | 5.29 | 10.55 | -49.82 |
| shareholders equity per share | 5.29 | 11.18 | -52.67 |
| interest debt per share | 0.81 | 0.9 | -9.70 |
| market cap | 135703350 | 372250607.04 | -63.55 |
| enterprise value | 151601730 | 357995647.04 | -57.65 |
| pe ratio | -1.0 | -1.29 | 22.39 |
| price to sales ratio | 163.1 | 36.27 | 349.65 |
| pocfratio | -1.09 | -1.72 | 36.62 |
| pfcf ratio | -1.09 | -1.71 | 36.50 |
| pb ratio | 1.16 | 1.67 | -30.92 |
| ptb ratio | 1.16 | 1.67 | -30.92 |
| ev to sales | 182.21 | 34.88 | 422.33 |
| enterprise value over ebitda | -1.16 | -1.32 | 12.02 |
| ev to operating cash flow | -1.22 | -1.66 | 26.38 |
| ev to free cash flow | -1.22 | -1.65 | 26.24 |
| earnings yield | -1.0 | -0.77 | -28.85 |
| free cash flow yield | -0.92 | -0.58 | -57.48 |
| debt to equity | 0.14 | 0.07 | 91.27 |
| debt to assets | 0.1 | 0.05 | 103.42 |
| net debt to ebitda | -0.12 | 0.05 | -331.71 |
| current ratio | 3.6 | 3.25 | 10.52 |
| interest coverage | -110.59 | -213.38 | 48.17 |
| income quality | 0.92 | 0.77 | 19.12 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 57.19 | 8.79 | 550.76 |
| research and ddevelopement to revenue | 106.34 | 18.29 | 481.56 |
| intangibles to total assets | 0 | 0.04 | -100.00 |
| capex to operating cash flow | -0.0 | -0.0 | 42.43 |
| capex to revenue | 0.39 | 0.09 | 308.40 |
| capex to depreciation | 0.09 | 0.18 | -48.06 |
| stock based compensation to revenue | 13.31 | 2.2 | 505.49 |
| graham number | 26.94 | 60.33 | -55.35 |
| roic | -1.01 | -1.16 | 13.08 |
| return on tangible assets | -0.78 | -0.86 | 8.77 |
| graham net net | 4.13 | 6.82 | -39.50 |
| working capital | 110542872 | 218374606 | -49.38 |
| tangible asset value | 117349129 | 209719524 | -44.04 |
| net current asset value | 97517806 | 189072134 | -48.42 |
| invested capital | 124995593 | 248974042 | -49.80 |
| average receivables | 7071722 | 9885130 | -28.46 |
| average payables | 12865635.5 | 24527850.5 | -47.55 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 1055.17 | 417.5 | 152.74 |
| days payables outstanding | 484.27 | 1400.15 | -65.41 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0.35 | 0.87 | -60.43 |
| payables turnover | 0.75 | 0.26 | 189.13 |
| inventory turnover | 0 | 0 | NaN |
| roe | -1.15 | -1.29 | 11.00 |
| capex per share | 0.01 | 0.05 | -70.31 |
ROE: Return on Equity (ROE) increased to -1.15 on 2023-12-31 from -1.29 on 2022-12-31, representing a change of 11.00%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 3.60 on 2023-12-31 from 3.25 on 2022-12-31, representing a change of 10.52%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -1.00 on 2023-12-31 from -1.29 on 2022-12-31, representing a change of 22.39%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.14 on 2023-12-31 from 0.07 on 2022-12-31, representing a change of 91.27%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| INO | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0.0 | -100.00 |
| net income per share | -894.28 | -1.19 | -75,348.62 |
| operating cash flow per share | -2997.66 | -1.04 | -288,916.92 |
| free cash flow per share | -2997.64 | -1.05 | -284,354.85 |
| cash per share | 3013.62 | 4.06 | 74,128.14 |
| book value per share | 2613.33 | 3.56 | 73,372.53 |
| tangible book value per share | 2613.33 | 3.56 | 73,372.53 |
| shareholders equity per share | 2613.33 | 3.56 | 73,372.53 |
| interest debt per share | 442.26 | 0 | NaN |
| market cap | 162652072.66 | 234173075.22 | -30.54 |
| enterprise value | -9079488927.34 | 212760883.22 | -4,367.46 |
| pe ratio | -0.0 | -1.82 | 99.91 |
| price to sales ratio | 0 | 2324.02 | -100.00 |
| pocfratio | -0.0 | -8.3 | 99.98 |
| pfcf ratio | -0.0 | -8.17 | 99.98 |
| pb ratio | 0.0 | 2.42 | -99.91 |
| ptb ratio | 0.0 | 2.42 | -99.91 |
| ev to sales | 0 | 2111.52 | -100.00 |
| enterprise value over ebitda | 0.33 | -6.77 | 104.90 |
| ev to operating cash flow | 0.11 | -7.54 | 101.43 |
| ev to free cash flow | 0.11 | -7.42 | 101.45 |
| earnings yield | -154.72 | -0.14 | -112,289.72 |
| free cash flow yield | -518.62 | -0.12 | -423,629.46 |
| debt to equity | 0.17 | 0 | NaN |
| debt to assets | 0.12 | 0 | NaN |
| net debt to ebitda | 0.34 | 0.68 | -50.43 |
| current ratio | 3.88 | 4.45 | -12.77 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.96 | 0.88 | 9.78 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 101294.99 | -100.00 |
| research and ddevelopement to revenue | 0 | 229.16 | -100.00 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.02 | 99.96 |
| capex to revenue | 0 | 4.49 | -100.00 |
| capex to depreciation | 0.0 | 0.55 | -99.96 |
| stock based compensation to revenue | 0 | 15.03 | -100.00 |
| graham number | 7251.45 | 9.74 | 74,354.02 |
| roic | -0.32 | -0.34 | 7.32 |
| return on tangible assets | -0.24 | -0.24 | 2.44 |
| graham net net | 1872.12 | 2.75 | 68,068.49 |
| working capital | 67785486000 | 91161277 | 74,257.76 |
| tangible asset value | 73540310000 | 96739207 | 75,919.14 |
| net current asset value | 57765259000 | 80503049 | 71,655.37 |
| invested capital | 80349896000 | 104491545 | 76,796.07 |
| average receivables | 932256332.5 | 2162373.5 | 43,012.64 |
| average payables | 3204369.5 | 7353000.5 | -56.42 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 1584.23 | -100.00 |
| days payables outstanding | 0 | 696.08 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0.06 | -100.00 |
| payables turnover | 0 | 0.13 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.34 | -0.33 | -2.69 |
| capex per share | 0.02 | 0.02 | 4.25 |
ROE: Return on Equity (ROE) decreased to -0.34 on 2024-09-30 Q3 from -0.33 on 2024-06-30 Q2, representing a change of -2.69%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 3.88 on 2024-09-30 Q3 from 4.45 on 2024-06-30 Q2, representing a change of -12.77%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.00 on 2024-09-30 Q3 from -1.82 on 2024-06-30 Q2, representing a change of 99.91%. Indicating an increase in the relative valuation of the company's stock.
Negative Sentiment: Discounted Cash Flow value is -1.7 which is lower than current price 4.77, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-14 19:53:10
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner - CMO Steve Egge - CCO Peter Kies - CFO Matthew Morrow - VP of Translational Sciences Conference Call Participants Jay Olson - Oppenheimer Roy Buchanan - Citizens JMP Sudan Loganathan - Stephens Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.
Sentiment: Positive
Publish Date: 2024-11-14 16:05:00
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1/2 trial Continued progress on preparing regulatory submissions for INO-3107 All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025 PLYMOUTH MEETING, Pa. , Nov. 14, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2024 and provided an update on recent company developments.
Sentiment: Positive
Publish Date: 2024-11-13 08:00:00
New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data supporting mechanism of action for INO-3107 to be presented at 36th International Papillomavirus Conference in Edinburgh, UK PLYMOUTH MEETING, Pa. , Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously observed in a Phase 1/2 trial of RRP patients.
Sentiment: Positive
Publish Date: 2024-11-06 16:05:00
PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference (Edinburgh, UK; November 12-15) Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enrichment in hallmark interferon alpha, interferon gamma and inflammatory molecular signatures in papilloma tissue of responders Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development Abstract Title: Clinical response to INO-3107 treatment for recurrent respiratory papillomatosis is associated with CD4 and CD8 T-Cell activity and cytotoxicity in patient airways Vaccines Summit (Boston, MA; November 13-15) Keynote presentation by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development Abstract Title: DNA Medicines Vaccine Platform for both Prophylactic and Therapeutic Applications: Case Studies in Ebola and Recurrent Respiratory Papillomatosis Abstracts from these conferences will be made available on INOVIO's website following each presentation.
Sentiment: Positive
Publish Date: 2024-11-06 08:00:00
PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024.
Sentiment: Positive
Publish Date: 2024-10-21 08:00:00
American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy : New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma International Society of Vaccines Conference : Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic; 81% of patients in the trial required fewer surgeries post-treatment when compared to baseline PLYMOUTH MEETING, Pa. , Oct. 21, 2024 /PRNewswire/ --Â INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, INO-3107, for which the company is preparing a Biologics License Application for targeted submission in mid-2025 under the U.S. Food and Drug Administration's Accelerated Approval Pathway Program.
Sentiment: Neutral
Publish Date: 2024-10-09 06:41:13
Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sentiment: Positive
Publish Date: 2024-10-02 16:15:00
PLYMOUTH MEETING, Pa. , Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan").
Sentiment: Neutral
Publish Date: 2024-10-01 08:00:00
PLYMOUTH MEETING, Pa. , Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways Date and Time: October 19, 2024, 6:00 - 8:15pm ET Location: Boston, MA ISV Congress 2024 Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 22, 2024, 4:20pm KSTLocation: Seoul, Korea Fall Voice Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 25 – October 26, 2024 Location: Phoenix, AZ World Vaccine Congress Europe Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIOTrack: Pre-Congress Workshop on Platform TechnologiesDate and Time: October 28, 2024, 10:00am CET Location: Barcelona, Spain Abstracts from these conferences will be made available on INOVIO's website following each presentation.
Sentiment: Positive
Publish Date: 2024-09-17 16:30:00
PLYMOUTH MEETING, Pa. , Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIOAbstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology Date and Time: September 18, 2024, 3:20pm – 3:35pm CET Location: Rome, Italy The abstract from the conference will be made available on INOVIO's website following the data presentation.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
